Video Interview with the team from Regencell Biosc
Post# of 6702
(Total Views: 205)
Posted On: 08/10/2022 10:59:53 AM
Video Interview with the team from Regencell Bioscience Holdings Limited (RGC).
SNN Live spoke with the team from RGC, including: Jay Lee, CEO of Regencell Bioscience Asia Limited, and Paul Niewiadomski, Independent Director, via Zoom to discuss. https://www.youtube.com/watch?v=Ixqb5B41s4Q
The overview and background of Regencell Bioscience Holdings Limited are covered in the video. Additionally, they discussed Paul Niewiadomski's history, including his experience with COVID 19 and how Regencell's TCM product helped him before he joined the company as an independent director. They also talked about the TCM formulation used by RGC, what makes it special and different, the results of recent efficacy trials, and last but not least, their objectives and plans for 2022.
For more information about Regencell Bioscience, please visit: https://www.regencellbioscience.com/
The interview contains forward-looking statements about Regencell Bioscience Holdings Limited. See RGC's periodic filings with the Securities and Exchange Commission for more complete information.
About Regencell Bioscience Holdings Limited:
Regencell Bioscience Holdings Limited is an early-stage bioscience company that commenced operations in Hong Kong is 2014. Regencell focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune system such as COVID. Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently to other markets as it deems appropriate. The Company formed a joint venture to offer COVID related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
https://finance.yahoo.com/news/regencell-desc...00084.html
SNN Live spoke with the team from RGC, including: Jay Lee, CEO of Regencell Bioscience Asia Limited, and Paul Niewiadomski, Independent Director, via Zoom to discuss. https://www.youtube.com/watch?v=Ixqb5B41s4Q
The overview and background of Regencell Bioscience Holdings Limited are covered in the video. Additionally, they discussed Paul Niewiadomski's history, including his experience with COVID 19 and how Regencell's TCM product helped him before he joined the company as an independent director. They also talked about the TCM formulation used by RGC, what makes it special and different, the results of recent efficacy trials, and last but not least, their objectives and plans for 2022.
For more information about Regencell Bioscience, please visit: https://www.regencellbioscience.com/
The interview contains forward-looking statements about Regencell Bioscience Holdings Limited. See RGC's periodic filings with the Securities and Exchange Commission for more complete information.
About Regencell Bioscience Holdings Limited:
Regencell Bioscience Holdings Limited is an early-stage bioscience company that commenced operations in Hong Kong is 2014. Regencell focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune system such as COVID. Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently to other markets as it deems appropriate. The Company formed a joint venture to offer COVID related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
https://finance.yahoo.com/news/regencell-desc...00084.html
(0)
(0)Scroll down for more posts ▼